Physician profile

Stephen Klacik

Pediatrics · Gainesville, GA

NPI 1922088293

$270.22

in general payments reported to CMS, 2019-2025

10 companies · none reported in 2025

Payments by year

General payments by program year, as reported to CMS.

What the payments were for

Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.

View as a table
Payment typeAmount (2023-2025)
Food and Beverage$23.59

Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.

Who reported paying

General payments only, as reported to CMS. Product names cover 2023-2025.

CompanyGeneral paymentsYearsTop products
Glaxosmithkline, LLC. $88.00 2020-2024 Bexsero, Pediarix, Menveo
Merck Sharp & Dohme LLC $37.04 2020-2021
Cranial Technologies, INC $34.42 2020-2021
Ultragenyx Pharmaceutical INC. $19.58 2022
Supernus Pharmaceuticals, INC. $18.90 2021
Sanofi Pasteur INC. $17.68 2021
Sobi, INC $16.37 2022
Shire North American Group INC $12.99 2019
Ironshore Pharmaceuticals INC. $12.95 2019
Tris Pharma INC $12.29 2020

Drugs and devices associated with these payments

CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.

If you want to bring it up

Most clinicians are glad to talk about this. A respectful way in:

These are normal questions. A good clinician will welcome them.

Share this page

Payment summary

Stephen Klacik

$270.22

in general payments reported 2019-2025

Years
2019-2024
Top company
Glaxosmithkline, LLC.

https://glasscript.com/doctor/178274/stephen-klacik

Source: CMS Open Payments, program years 2019-2025. Payments are legal and often routine.

Keep an eye on this page

Get an email when the next June refresh changes this page. No account needed.

Watch this doctor

Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.